Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with highrisk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care.

Andrea Palloni, G.F. (2019). Adjuvant treatment in biliary tract cancer. TRANSLATIONAL CANCER RESEARCH, 8, 289-296 [10.21037/tcr.2018.08.17].

Adjuvant treatment in biliary tract cancer

Andrea Palloni;Giorgio Frega;Stefania De Lorenzo;Alessandro Rizzo;Francesca Abbati;Marzia Deserti;Simona Tavolari;Giovanni Brandi
2019

Abstract

Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients’ long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with highrisk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care.
2019
Andrea Palloni, G.F. (2019). Adjuvant treatment in biliary tract cancer. TRANSLATIONAL CANCER RESEARCH, 8, 289-296 [10.21037/tcr.2018.08.17].
Andrea Palloni, Giorgio Frega, Stefania De Lorenzo, Alessandro Rizzo, Francesca Abbati, Marzia Deserti, Simona Tavolari, Giovanni Brandi
File in questo prodotto:
File Dimensione Formato  
Adjuvant treatment in biliary tract cancer.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 228.97 kB
Formato Adobe PDF
228.97 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/676402
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact